| Mikenna Marie O'donnell, OTR/L | |
|
202 S 4th St W, Baker, MT 59313-9156 | |
| (406) 778-3331 | |
| (406) 778-5163 |
| Full Name | Mikenna Marie O'donnell |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 202 S 4th St W, Baker, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033676630 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTP-OT-LIC-6625 (Montana) | Primary |
| Provider Name | Fallon Medical Complex Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1386700763 PECOS PAC ID: 0941119499 Enrollment ID: O20040614000391 |
News Archive
Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.
Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.
APC Group, Inc. reports unaudited revenues increased 30%, to $258,984 for the twelve months ended November 30th, 2009 compared to $198,344 for the twelve months ended November 30th, 2008.
Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.
› Verified 7 days ago
| Provider Name | Fallon Medical Complex Inc |
|---|---|
| Provider Type | Part A Provider - Critical Access Hospital |
| Provider Identifiers | NPI Number: 1316965346 PECOS PAC ID: 0941119499 Enrollment ID: O20061104000600 |
News Archive
Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.
Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.
APC Group, Inc. reports unaudited revenues increased 30%, to $258,984 for the twelve months ended November 30th, 2009 compared to $198,344 for the twelve months ended November 30th, 2008.
Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mikenna Marie O'donnell, OTR/L Po Box 1015, Baker, MT 59313-1015 Ph: (406) 702-5026 | Mikenna Marie O'donnell, OTR/L 202 S 4th St W, Baker, MT 59313-9156 Ph: (406) 778-3331 |
News Archive
Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.
Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.
APC Group, Inc. reports unaudited revenues increased 30%, to $258,984 for the twelve months ended November 30th, 2009 compared to $198,344 for the twelve months ended November 30th, 2008.
Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.
› Verified 7 days ago